Expertise in
7
conditions

Dr. Daruka Mahadevan

Oncology
American Transitional Hospital Inc
3838 N Campbell Ave, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
American Transitional Hospital Inc
3838 N Campbell Ave, 
Tucson, AZ 

Overview

Daruka Mahadevan is an Oncologist practicing medicine in Tucson, Arizona.

Dr. Mahadevan is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Pancreatic Ductal Adenocarcinoma, Gastrointestinal Stromal Tumor, and Peripheral T-Cell Lymphoma.

He is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 11 clinical trials. Dr. Mahadevan is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in AZ

Hospital Affiliations

University Health System
UT Health San Antonio Multispecialty & Research Ho

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

American Transitional Hospital Inc
3838 N Campbell Ave, Tucson, AZ 85719
Other Locations
University of Texas Health Science Center at San Antonio
7979 Wurzbach Rd, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

105 Total Publications

Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: August 11, 2026
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Banner-University Medical Center Tucson Campus

1625 North Campbell Avenue, 
Tucson, AZ 
 (2.3 miles away)
520-694-0111
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (2.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Garland is an Oncologist practicing medicine in Tucson, Arizona. Dr. Garland is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Garland is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Garland is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required
Before you request

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (2.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy advancing medicine through academics and excellent patient care.My particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers. Dr. Scott is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Scott is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine. Dr. Scott is currently accepting new patients.

Frequently Asked Questions about Dr. Daruka Mahadevan

How do I make an appointment with Dr. Daruka Mahadevan?

You can book an appointment with Dr. Daruka Mahadevan by calling their office at 520-694-2873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daruka Mahadevan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daruka Mahadevan is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daruka Mahadevan specialize in?

While Dr. Daruka Mahadevan is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Pancreatic Ductal Adenocarcinoma, and Gastrointestinal Stromal Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daruka Mahadevan participate in research or clinical trials?

Yes. Dr. Daruka Mahadevan has published 105 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Daruka Mahadevan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daruka Mahadevan accept my insurance?

Dr. Daruka Mahadevan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 520-694-2873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mahadevan's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 47 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile